Early Insights from Commercialization of Gene Therapies in Europe
- PMID: 28218692
- PMCID: PMC5333067
- DOI: 10.3390/genes8020078
Early Insights from Commercialization of Gene Therapies in Europe
Abstract
After years of research and development, gene therapies are now becoming a commercial reality with several products approved by European regulatory authorities [...].
Keywords: Glybera; Imlygic; Strimvelis; commercialization; gene therapies; market access; payers; reimbursement.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Federal Joint Committee. [(accessed on 22 December 2016)]. Available online: http://www.english.g-ba.de/downloads/91-1028-146/Alipogene%20tiparvovec_....
-
- HAS-Sante. [(accessed on 22 December 2016)]. Available online: http://www.has-sante.fr/portail/upload/docs/evamed/CT-14224_GLYBERA_PIC_....
-
- National Institute of Clinical Excellence. [(accessed on 22 December 2016)]. Available online: https://www.nice.org.uk/guidance/indevelopment/gid-tag509.
-
- IQWiG. [(accessed on 22 December 2016)]. Available online: https://www.iqwig.de/en/press/press-releases/press-releases/talimogene-l....
-
- NICE. [(accessed on 22 January 2017)]. Available online: https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%....
LinkOut - more resources
Full Text Sources
Other Literature Sources
